
background
In December 2023, the Japanese government launched the "Conceptual Council for Prompt Delivery of the Latest Pharmaceuticals to the Public through Enhanced Drug Discovery" in response to recent issues such as drug lag/drug loss and declining international competitiveness of the pharmaceutical industry.
The interim summary released in May 2024 indicated a policy of strengthening Japan's drug discovery capabilities by actively attracting know-how and funds from domestic and foreign pharmaceutical companies, venture capitalists (VCs), and other sources. In addition, the "Basic Policies for Economic and Fiscal Management and Reform 2024: Realization of a Growth-Oriented Economy Driven by Wage Increases and Investment" (Kotto Policy 2024) clearly states that MEDISO's functions will be strengthened.
MRI, which operates MEDISO on behalf of the Ministry of Health, Labour and Welfare (MHLW), supports medical startups and academia aiming to commercialize innovative medical solutions by providing consultation advice and acceleration programs in collaboration with various stakeholders in Japan and overseas, and by hosting matchmaking events with overseas VC firms. MRI supports medical startups and academia aiming to commercialize innovative medical solutions through consultation, advice, and acceleration programs.
Alliance Overview and Outlook
This alliance will allow MRI to leverage the expertise of Astellas Pharma Inc., a leading Japanese pharmaceutical company, in drug discovery and development to provide more sophisticated support for the commercialization of seeds from Japanese medical startups and academia that MEDISO provides.
Under the terms of the agreement, Astellas will provide research space and office space in SakuLabTM-Tsukuba, which was established on the premises of the Tsukuba Research Center, for the Acceleration Program for Drug Discovery Startups, one of the various support programs implemented by MEDISO. The program provides access to research and office space in SakuLabTM-Tsukuba, which was established on the premises of the Tsukuba Research Center.
When a drug discovery startup moves into SakuLabTM-Tsukuba, it will be able to accelerate its drug discovery research by utilizing the network of other tenants and Astellas researchers, in addition to consultation support provided by Astellas experts in various fields.
Commenting on the partnership, Keishi Suzuki, Executive Officer and General Manager of Public Innovation Division at MRI, said, "We are very encouraged to partner with Astellas Pharma Inc. in supporting drug discovery startups in MEDISO. It is essential for drug discovery start-ups to seek out the latest knowledge and know-how from outside sources in order to advance the commercialization of their research seeds. The early introduction of the perspective of Astellas, a globally active pharmaceutical company, will accelerate the commercialization of research seeds, and is expected to have an effective impact on the Japanese drug discovery ecosystem. We will leverage the strengths of both companies to bring innovative medical solutions to patients in Japan and around the world as quickly as possible. said Dr. Katsunori Kato, President and CEO of the company.
Tadaaki Taniguchi, Astellas' Chief Research & Development Officer (CRDO), said, "We are very pleased to conclude a basic agreement between MRI and MEDISO for drug discovery start-up support services. Astellas hopes to nurture and blossom innovative ideas and technologies together by providing the knowledge, experience, and overseas networks that we have cultivated through our R&D to date to meet the needs of startups and acamidea that are challenging innovation. We hope that the conclusion of this basic agreement will further strengthen and accelerate drug discovery research by Japanese drug discovery startups and lead to the creation of innovative medical solutions.
Through their collaboration, Mitsubishi Research Institute and Astellas Pharma Inc. aim to create innovative pharmaceutical products originating from Japan.
Related Information
MEDISO is entrusted with the "Medical Venture Total Support Project (MEDISO)" by the Ministry of Health, Labour and Welfare (News Release 2025.6.13)
Mitsubishi Research Institute, Inc.
| name of company | Mitsubishi Research Institute, Inc. |
| Establishment | May 1970 |
| Location | 2-10-3 Nagatacho, Chiyoda-ku, Tokyo |
| representative | Kenji Huda |
| uniform resouce locator | https://www.mri.co.jp/ |









